AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

ALLIANCE PHARMA PLC

Share Issue/Capital Change Dec 29, 2020

7478_rns_2020-12-29_be7c5ef6-70dd-41c7-9e58-3ac624384712.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 0314K

Alliance Pharma PLC

29 December 2020

For immediate release 29 December 2020

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Block Listing Six Monthly Return

Name of applicant: ALLIANCE PHARMA PLC
Names of schemes: a)     The Alliance Pharma plc Approved Share Option Plan 2005

b)    The Alliance Pharma plc Share Option Plan 2006

c)     The Alliance Pharma plc Company Share Option Plan 2015
Period of return: From: 28 June 2020 To: 28 December 2020
Number of securities originally admitted at date of admission: 25,000,000 ordinary shares of 1p each

28 June 2017
Balance of unallotted securities under schemes from previous return: a)     356,536

b)    5,362,778

c)     14,923,223
Plus:  The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for): a)     Nil

b)    Nil

c)     Nil
Less:  Number of securities issued/allotted under schemes during period: a)  63,164

b) 96,156

c)  1,701,727
Equals:  Balance under schemes not yet issued/allotted at end of period: a)     293,372

b)    5,266,622

c)     13,221,496
Name of contact: Chris Chrysanthou, Company Secretary
Telephone number of contact: Tel. +44 (0)1249 705166

For further information:

Alliance Pharma plc                                                                                                                        + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

Buchanan                                                                                                                                         + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited                                                                                                             + 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

Corporate Broking: James Black

Investec Bank plc                                                                                                                           +44 (0) 20 7597 5970

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

About Alliance Pharma

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website:  www.alliancepharmaceuticals.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRKKCBQBBDDKBB

Talk to a Data Expert

Have a question? We'll get back to you promptly.